The Transcatheter mitral valve replacement Market, also known as the bicuspid valve or left atrio-ventricular valve, is a dual-flap valve in the heart that lies between the left atrium and the left ventricle. The mitral valve and the tricuspid valve are known collectively as the atrio-ventricular valves because they lie between the atria and the ventricles of the heart. The mitral valve manages blood flow between left atrium and left ventricle; and prevents backward flow of the blood into left atrium. Mitral regurgitation is leakage of blood backward through the mitral valve each time the left ventricle contracts. This is a most common mitral valve disorder that causes abnormal blood flow. As a remedy for this problem, surgeons use mitral surgical vale repair procedures or transcatheter replacement methods.
Some of the key driving factors attributing to the growth of this market include increasing number of patients with mitral valve disorders. Approximately 7 million people in the U.S., suffer from mitral regurgitation in the U.S., and they represent almost 2% of the nation’s population. Similarly, approximately the same number of people suffer from the condition in Europe. This group includes 4.1 million people who have moderate to severe mitral regurgitation. The number of new patients suffering with mitral regurgitation disease added each year is 250,000. Among this 4.1 million patients, only about 20% or 1.67 million are eligible for the treatment. This creates huge opportunity for the global transcatheter mitral valve replacement market.
In addition, increasing adoption of minimally invasive procedures over traditional surgical open heart procedures, reduction in hospital stays, low risk of infection, minimal blood loss are further propelling the market. According to World Health Organization (WHO), it has been estimated that the number of people suffering from cardiovascular diseases will increase to 22.2 million by 2030. The market for TMVR is expected to reach around USD 3.0 billion by 2022, growing at a CAGR of 15.9% during the forecast period of 2016e to 2022f. However, there are certain restraining factors which could hamper the growth of this market, which includes, high costs associated with the LMVD implantation compared to other therapies available for CVD diseases.
Geographically, North America is leading contributor to the market and is expected to retain its position during the forecast period. Nonetheless, the market for Asia-Pacific region is expected to grow at a faster rate owing to increasing prevalence of CVD diseases, growing awareness about minimally invasive surgical procedures among the population, improving healthcare infrastructure, rise in healthcare spending, and favorable government policies.
- Edwards Lifesciences Corp.
- Abbott Laboratories
- Micro Interventional Devices